Emma Barrow

Summary

Country: UK

Publications

  1. ncbi Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer
    E Barrow
    Department of General Surgery, Manchester Royal Infirmary, St Mary s Hospital, Manchester, UK
    Br J Surg 95:868-75. 2008
  2. ncbi Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations
    E Barrow
    Department of General Surgery, Manchester Royal Infirmary, Manchester, UK
    Clin Genet 74:233-42. 2008
  3. ncbi Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations
    E Barrow
    Department of General Surgery, Manchester Royal Infirmary, Manchester, UK
    Clin Genet 75:141-9. 2009
  4. ncbi Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome
    Emma Barrow
    Department of General Surgery, Manchester Royal Infirmary, Manchester, M13 9WL, UK
    Histopathology 56:331-44. 2010
  5. ncbi A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome
    Emma Barrow
    Department of General Surgery, Manchester Royal Infirmary, Oxford Road, Manchester, UK
    J Clin Pathol 64:208-14. 2011

Detail Information

Publications5

  1. ncbi Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer
    E Barrow
    Department of General Surgery, Manchester Royal Infirmary, St Mary s Hospital, Manchester, UK
    Br J Surg 95:868-75. 2008
    ..The evidence suggests that patients with tumours caused by defective DNA MMR do not benefit from 5-fluorouracil (5-FU)-based chemotherapy...
  2. ncbi Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations
    E Barrow
    Department of General Surgery, Manchester Royal Infirmary, Manchester, UK
    Clin Genet 74:233-42. 2008
    ..Current colonoscopic screening guidelines are appropriate...
  3. ncbi Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations
    E Barrow
    Department of General Surgery, Manchester Royal Infirmary, Manchester, UK
    Clin Genet 75:141-9. 2009
    ..0003). Gastric cancer risk in those born after 1935 does not justify surveillance. These penetrance estimates have been corrected for ascertainment bias and are appropriate for those referred to a high-risk clinic...
  4. ncbi Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome
    Emma Barrow
    Department of General Surgery, Manchester Royal Infirmary, Manchester, M13 9WL, UK
    Histopathology 56:331-44. 2010
    ..To assess semiquantitative immunohistochemistry as used in the diagnosis of Lynch syndrome...
  5. ncbi A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome
    Emma Barrow
    Department of General Surgery, Manchester Royal Infirmary, Oxford Road, Manchester, UK
    J Clin Pathol 64:208-14. 2011
    ..Quantum dots (QDs) are novel fluorescent labels that enable quantitative multiplex staining. This study compared their use with quantitative 3,3'-diaminobenzidine (DAB) IHC for the diagnosis of Lynch Syndrome...